Balyasny Asset Management
EDIT icon

Balyasny Asset Management’s Editas Medicine EDIT Stock Holding History

Balyasny Asset Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-97,500
Closed -$3.49M – 1749
2018
Q2 		$3.49M Buy
+97,500
New +$3.45M 0.02% 767

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Balyasny Asset Management's EDIT Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Editas Medicine (EDIT) in Q2 2026: 37,638 shares worth $122K. The stake represents ﹤0.01% of the portfolio and ranks #2872 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in EDIT as recently as Q4 2024.

Balyasny Asset Management first reported a position in EDIT in Q3 2016 and has held it in 17 quarters since. The position peaked at $3.72M in Q2 2022. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Balyasny Asset Management held 37,638 shares of Editas Medicine worth $122K as of Q2 2026.
  • Editas Medicine was a new Balyasny Asset Management position in Q2 2026.
  • Editas Medicine made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2872 holding.
  • Balyasny Asset Management first reported a position in Editas Medicine in Q3 2016 and has held it in 17 quarters since.
  • Balyasny Asset Management's Editas Medicine position peaked at $3.72M in Q2 2022.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.